CNS Year in Review: Going Digital
Health Advances
APRIL 6, 2023
Notably several companies have begun to integrate digital biomarkers as exploratory endpoints in their clinical trials. Thus, CNS-focused biopharmas should carefully consider digital biomarkers as they chart development paths. Biopharma companies have taken notice of these technologies and invested in them.
Let's personalize your content